May 3, 2021

Future Downstream Process Development Solutions for Advanced Therapies


Click here to view more Industry Leader Q&As >> 

Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva, provides insight into solutions for advanced therapies. 

Topics covered include what molecules are most commonly involved in advanced therapies and key challenges in process development for the downstream purification of therapies such as mRNA, viral vectors, and plasmids. Also discussed are innovative projects on the horizon at Cytiva to address the previously mentioned challenges.

Related Content

Q&As with Industry Leaders

mRNA manufacturing strategies

Manufacturing of viral vectors 

Purification of plasmids 

Oligonucleotide therapeutics